Amicus Therapeutics, Inc. (FOLD) Stock Profile & Financial OverviewAmicus Therapeutics, Inc.
FOLD Company Overview & Business Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Key Information
Current Trend for FOLD
An assessment of the current trend environment for FOLD, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for FOLD is a Strong Momentum Environment (High Conviction Uptrend).
Daily and weekly trends are in bullish alignment, forming a strong medium-term uptrend.
- The weekly backdrop provides strong tailwinds, confirming that the medium-term path of least resistance is upward.
- Price is currently trending at a healthy distance, sitting 2.15 ATR away from the adaptive KAMA baseline.
- The market is maintaining a healthy 'Higher-High, Higher-Low' sequence, confirming buyer control.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, FOLD in a strong expansion phase; Long-term trend is bullish.
Trend Strength: FOLD last closed at 14.25, trading 1.0 ATR above the adaptive KAMA baseline (13.74). Technical Classification: Confirmed High-Momentum Uptrend.
Trend Score: Technical Score: 95/100. Classification: Strong/Established. Alignment: High. Logic: Full multi-timeframe alignment with strong momentum filters.
SuperTrend Risk: Structural Support: Adaptive SuperTrend at 9.78. This level serves as the calculated invalidation point for the current upward structure.
Risk Skew: Multi-timeframe risk skew is currently assessed as Constructive Upside. Daily and weekly trends are in high-quality alignment with healthy momentum. Risk skew favors continued upside follow-through from current levels.
Key Levels: In this bullish structure, key support is anchored by immediate support (KAMA) at 13.74, with the critical trend-guard (SuperTrend) at 9.78.